ESMO 2017: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma
Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage…
Browsing: anti-programmed death-1 (PD-1) antibody nivolumab